Latest National Cancer Institute Stories
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute. Metastatic colorectal cancer patients whose tumors harbor mutations in KRAS (and to a lesser extent, in BRAF) are unlikely to respond to costly anti-EGFR therapies. Screening of patients who are...
Researchers have identified a link between higher dietary glycemic load and total carbohydrate intake and increased risk of cancer recurrences or death among stage 3 colon cancer patients, a finding that suggests that diet and lifestyle modification can have a role in improving patient survival, according to a study published November 7 in the Journal of the National Cancer Institute. The role of one's lifestyle behavior has been shown to play an important role in the development of...
Brett Smith for redOrbit.com - Your Universe Online Many experts and organizations have been advocating regular physical exercise—like the NFL’s Play 60, which encourages kids to be active for an hour each day, and every so often a study comes along that reinforces the benefits of exercise for people of any age. According to a new report from an international team of researchers, recently published in the open-access journal PLoS Medicine, regular physical activity during leisure...
OAKLAND, Calif., Nov. 1, 2012 /PRNewswire/ -- This November and December, The Glad Products Company is encouraging consumers to bake a difference for Cookies for Kids' Cancer(TM), a non-profit organization that supports research for new and improved treatments for pediatric cancer through cookie exchanges and bake sales. Through the Glad® Holiday Cookie Exchange, Glad is turning cookies into currency by donating up to $1 for every cookie sent, sold or exchanged this November and...
SAVAGE, Md., Oct. 24, 2012 /PRNewswire/ -- Chesapeake PERL has received a Small Business Innovation Research award from the National Cancer Institute to continue development of a protein nanoparticle linked to an antitumor agent as a potential lung cancer therapeutic. C-PERL collaborators in the laboratory of Dr. Leonard Rome, Professor of Biological Chemistry at UCLA have identified and characterized the vault particle, a unique nanoparticle structure ubiquitous in eukaryotes....
WASHINGTON, Oct. 24, 2012 /PRNewswire-USNewswire/-- In response to "Consumption of Artificial Sweetener and Sugar Containing Soda and the Risk of Lymphoma and Leukemia in Men and Women," a study published today in the American Journal of Clinical Nutrition, the American Beverage Association issued the following statement: Statement: "The authors said it best: their study has 'limited application' and their findings may be 'due entirely to chance.' We agree. The fact is:...
By the National Cancer Institute Editor's Note: The following article is part of the monthly Lifelines education and awareness print series that the National Cancer Institute provides to African American news and information outlets. BETHESDA, Md., Oct. 23, 2012 /PRNewswire-USNewswire/ -- If you or a family member receives a cancer diagnosis you will likely be looking for information about the disease. Or you may be interested in ways to prevent cancer or want information about how...
Combined folic acid, vitamin B6 and vitamin B12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute. Between 28% and 35% of the U.S. population reported to take dietary supplements containing folic acid, vitamin B6, and vitamin B12, and previous in vitro and animal studies have shown that B vitamins combat...
ANN ARBOR, Mich., Oct. 11, 2012 /PRNewswire/ -- The Sarcoma Alliance for Research through Collaboration (SARC), a not-for-profit consortium dedicated to providing infrastructure to support collaborative sarcoma research, announced today that it has received a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). This grant will provide $11.5 million over five years in support of sarcoma translational research. Sarcoma is a relatively...
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute. Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared...
